Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.15 EUR | -2.54% | -17.27% | +38.55% |
2021 | Aap Implantate AG Announces Sales Results for the Second Quarter and Half Year Ended 30 June 2021 | CI |
2021 | Aap Implantate Ag Reports Earnings Results for the Full Year Ended December 31, 2020 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company's share price in relation to its net book value makes it look relatively cheap.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+38.55% | 12.31M | - | ||
-5.56% | 181B | C+ | ||
-0.11% | 108B | C | ||
-6.17% | 66.12B | A | ||
+2.64% | 50.65B | B- | ||
+6.58% | 43.66B | B- | ||
+4.91% | 41.3B | B+ | ||
+21.98% | 31.6B | B | ||
+14.45% | 25.03B | A- | ||
-5.81% | 24.16B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AAQ1 Stock
- Ratings aap Implantate AG